• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

福莫特罗在抑制中性粒细胞反应性方面比沙美特罗更有效。

Formoterol is more effective than salmeterol in suppressing neutrophil reactivity.

作者信息

Tintinger Gregory R, Theron Annette J, Steel Helen C, Feldman Charles, Anderson Ronald

机构信息

Department of Internal Medicine, Faculty of Health Sciences, University of Pretoria, Pretoria, South Africa; Institute for Cellular and Molecular Medicine, Department of Immunology, Faculty of Health Sciences, University of Pretoria, Pretoria, South Africa.

Institute for Cellular and Molecular Medicine, Department of Immunology, Faculty of Health Sciences, University of Pretoria, Pretoria, South Africa; Tshwane Academic Division of the National Health Laboratory Service, Pretoria, South Africa.

出版信息

ERJ Open Res. 2015 Sep 14;1(1). doi: 10.1183/23120541.00014-2015. eCollection 2015 May.

DOI:10.1183/23120541.00014-2015
PMID:27730134
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5005134/
Abstract

http://ow.ly/Qr9fE.

摘要

http://ow.ly/Qr9fE. （此为网址，无法准确翻译其内容，保留原文形式）

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bccd/5005134/6835baf05bca/00014-2015.02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bccd/5005134/9f52c259f720/00014-2015.01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bccd/5005134/6835baf05bca/00014-2015.02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bccd/5005134/9f52c259f720/00014-2015.01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bccd/5005134/6835baf05bca/00014-2015.02.jpg

相似文献

1
Formoterol is more effective than salmeterol in suppressing neutrophil reactivity.福莫特罗在抑制中性粒细胞反应性方面比沙美特罗更有效。
ERJ Open Res. 2015 Sep 14;1(1). doi: 10.1183/23120541.00014-2015. eCollection 2015 May.
2
Comparison of the anti-inflammatory properties of formoterol, salbutamol and salmeterol in guinea-pig skin and lung.福莫特罗、沙丁胺醇和沙美特罗在豚鼠皮肤和肺部抗炎特性的比较
Br J Pharmacol. 1993 Oct;110(2):613-8. doi: 10.1111/j.1476-5381.1993.tb13855.x.
3
Efficacy of salmeterol and formoterol combination treatment in mice with chronic obstructive pulmonary disease.沙美特罗与福莫特罗联合治疗对慢性阻塞性肺疾病小鼠的疗效。
Exp Ther Med. 2018 Feb;15(2):1538-1545. doi: 10.3892/etm.2017.5562. Epub 2017 Nov 24.
4
Efficacy and safety of aclidinium/formoterol versus salmeterol/fluticasone: a phase 3 COPD study.阿地溴铵/福莫特罗与沙美特罗/氟替卡松治疗慢性阻塞性肺疾病的疗效和安全性：一项 3 期 COPD 研究。
Eur Respir J. 2016 Oct;48(4):1030-1039. doi: 10.1183/13993003.00216-2016. Epub 2016 Aug 4.
5
Effect on lung function and morning activities of budesonide/formoterol versus salmeterol/fluticasone in patients with COPD.布地奈德/福莫特罗对 COPD 患者肺功能和清晨活动的影响优于沙美特罗/氟替卡松。
Ther Adv Respir Dis. 2009 Aug;3(4):1-11. doi: 10.1177/1753465809344870. Epub 2009 Sep 4.
6
Comparative analysis of budesonide/formoterol and fluticasone/salmeterol combinations in COPD patients: findings from a real-world analysis in an Italian setting.布地奈德/福莫特罗与氟替卡松/沙美特罗联合用药在慢性阻塞性肺疾病患者中的比较分析：意大利真实世界分析结果
Int J Chron Obstruct Pulmon Dis. 2016 Nov 4;11:2749-2755. doi: 10.2147/COPD.S114554. eCollection 2016.
7
Long-acting beta2 agonists in the management of stable chronic obstructive pulmonary disease.长效β2受体激动剂在稳定期慢性阻塞性肺疾病管理中的应用
Drugs. 2000 Aug;60(2):307-20. doi: 10.2165/00003495-200060020-00005.
8
Bronchodilator effect of an inhaled combination therapy with salmeterol + fluticasone and formoterol + budesonide in patients with COPD.沙美特罗+氟替卡松与福莫特罗+布地奈德吸入联合疗法对慢性阻塞性肺疾病患者的支气管扩张作用。
Respir Med. 2003 May;97(5):453-7. doi: 10.1053/rmed.2002.1455.
9
Faster onset of action of formoterol versus salmeterol in patients with chronic obstructive pulmonary disease: a multicenter, randomized study.福莫特罗与沙美特罗治疗慢性阻塞性肺疾病起效更快：一项多中心随机研究
Pulm Pharmacol Ther. 2009 Feb;22(1):44-9. doi: 10.1016/j.pupt.2008.11.010. Epub 2008 Nov 30.
10
Combination of budesonide/formoterol more effective than fluticasone/salmeterol in preventing exacerbations in chronic obstructive pulmonary disease: the PATHOS study.布地奈德/福莫特罗联合治疗在预防慢性阻塞性肺疾病急性加重方面优于氟替卡松/沙美特罗：PATHOS 研究。
J Intern Med. 2013 Jun;273(6):584-94. doi: 10.1111/joim.12067. Epub 2013 Apr 1.

引用本文的文献

1
Fixed-dose combination fluticasone/formoterol for asthma treatment in a real-world setting: meta-analysis of exacerbation rates and asthma control.固定剂量复方氟替卡松/福莫特罗在真实临床环境中用于哮喘治疗：加重率和哮喘控制的荟萃分析
Eur Clin Respir J. 2023 Feb 6;10(1):2174642. doi: 10.1080/20018525.2023.2174642. eCollection 2023.

本文引用的文献

1
The long-acting β2 -adrenoceptor agonist olodaterol attenuates pulmonary inflammation.长效β2肾上腺素能受体激动剂奥洛他定可减轻肺部炎症。
Br J Pharmacol. 2015 Jul;172(14):3537-47. doi: 10.1111/bph.13143. Epub 2015 May 12.
2
β2 adrenergic agonist attenuates house dust mite-induced allergic airway inflammation through dendritic cells.β2肾上腺素能激动剂通过树突状细胞减轻屋尘螨诱导的过敏性气道炎症。
BMC Immunol. 2014 Oct 30;15:39. doi: 10.1186/s12865-014-0039-y.
3
Extracellular matrix composition is modified by β₂-agonists through cAMP in COPD.
β₂-激动剂通过 cAMP 改变 COPD 细胞外基质组成。
Biochem Pharmacol. 2014 Oct 1;91(3):400-8. doi: 10.1016/j.bcp.2014.07.026. Epub 2014 Aug 12.
4
The beta-2-adrenoreceptor agonists, formoterol and indacaterol, but not salbutamol, effectively suppress the reactivity of human neutrophils in vitro.β-2肾上腺素能受体激动剂福莫特罗和茚达特罗，但不是沙丁胺醇，在体外能有效抑制人中性粒细胞的反应性。
Mediators Inflamm. 2014;2014:105420. doi: 10.1155/2014/105420. Epub 2014 Mar 6.
5
Long-acting inhaled therapy (beta-agonists, anticholinergics and steroids) for COPD: a network meta-analysis.慢性阻塞性肺疾病的长效吸入疗法（β受体激动剂、抗胆碱能药物和类固醇）：一项网状荟萃分析。
Cochrane Database Syst Rev. 2014 Mar 26;2014(3):CD010844. doi: 10.1002/14651858.CD010844.pub2.
6
A comparison of long-term anti-inflammatory effect of two ICS/LABA combination inhalers; fix-dosed maintenance therapy with budesonide/formoterol and salmeterol/fluticasone.两种吸入性糖皮质激素/长效β2受体激动剂联合制剂的长期抗炎效果比较：布地奈德/福莫特罗与沙美特罗/氟替卡松的固定剂量维持治疗
Allergol Int. 2014 Mar;63(1):103-11. doi: 10.2332/allergolint.13-OA-0590.
7
Comparison of the effects of budesonide/formoterol maintenance and reliever therapy with fluticasone/salmeterol fixed-dose treatment on airway inflammation and small airway impairment in patients who need to step-up from inhaled corticosteroid monotherapy.比较布地奈德/福莫特罗维持和缓解治疗与氟替卡松/沙美特罗固定剂量治疗对需要从吸入性皮质激素单药治疗升级的患者气道炎症和小气道损害的影响。
Pulm Pharmacol Ther. 2014 Apr;27(2):190-6. doi: 10.1016/j.pupt.2013.12.003. Epub 2014 Jan 2.
8
Can the anti-inflammatory activities of β2-agonists be harnessed in the clinical setting?β2受体激动剂的抗炎活性能否在临床环境中得到应用？
Drug Des Devel Ther. 2013 Nov 22;7:1387-98. doi: 10.2147/DDDT.S50995. eCollection 2013.
9
Switching from salmeterol/fluticasone to formoterol/budesonide combinations improves peripheral airway/alveolar inflammation in asthma.从沙美特罗/氟替卡松转换为福莫特罗/布地奈德联合治疗可改善哮喘的外周气道/肺泡炎症。
Pulm Pharmacol Ther. 2014 Feb;27(1):52-6. doi: 10.1016/j.pupt.2013.04.001. Epub 2013 Apr 11.
10
Combination of budesonide/formoterol more effective than fluticasone/salmeterol in preventing exacerbations in chronic obstructive pulmonary disease: the PATHOS study.布地奈德/福莫特罗联合治疗在预防慢性阻塞性肺疾病急性加重方面优于氟替卡松/沙美特罗：PATHOS 研究。
J Intern Med. 2013 Jun;273(6):584-94. doi: 10.1111/joim.12067. Epub 2013 Apr 1.